Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Yoder, Kristine E ^a   Bundschuh, Ralf ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUIDE RNA;

CD4+ T LYMPHOCYTE; CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DOUBLE STRANDED DNA BREAK; GENE EDITING; GENE TARGETING; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PROCEDURES; VIROLOGY; VIRUS REPLICATION;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-CAS SYSTEMS; DNA BREAKS, DOUBLE-STRANDED; GENE EDITING; GENE TARGETING; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; RNA, GUIDE; VIRUS REPLICATION;

EID: 84978370136     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29530     Document Type: Article

References (36)

1. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5, 512-517, doi: 10.1038/8394 (1999).
2. Ebina, H., Misawa, N., Kanemura, Y. & Koyanagi, Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3, 2510 (2013).
3. Hu, W. et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 111, 11461-11466 (2014).
4. Liao, H. K. et al. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nat Commun 6, 6413 (2015).
5. Zhu, W. et al. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology 12, 22 (2015).
6. Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232 (2013).
7. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
8. Rothkamm, K. & Lobrich, M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA 100, 5057-5062, doi: 10.1073/pnas.0830918100 (2003).
9. Pannunzio, N. R., Li, S., Watanabe, G. & Lieber, M. R. Non-homologous end joining often uses microhomology: implications for alternative end joining. DNA Repair (Amst) 17, 74-80, doi: 10.1016/j.dnarep.2014.02.006 (2014).
10. Kim, H. & Kim, J. S. A guide to genome engineering with programmable nucleases. Nat Rev Genet 15, 321-334, doi: 10.1038/ nrg3686 (2014).
11. Cai, M. & Yang, Y. Targeted genome editing tools for disease modeling and gene therapy. Curr Gene Ther 14, 2-9 (2014).
12. Dampier, W., Nonnemacher, M. R., Sullivan, N. T., Jacobson, J. M. & Wigdahl, B. HIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a Cure. MOJ Immunol 1, doi: 10.15406/moji.2014.01.00022 (2014).
13. Hirsch, M. S. et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. Jama 279, 1984-1991 (1998).
14. Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G. & Hughes, S. H. Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84, 9864-9878 (2010).
15. Rawson, J. M., Landman, S. R., Reilly, C. S. & Mansky, L. M. HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology 12, 60 (2015).
16. Kieffer, T. L. et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189, 1452-1465, doi: 10.1086/382488 (2004).
17. Zhang, L. et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340, 1605-1613, doi: 10.1056/NEJM199905273402101 (1999).
18. Frenkel, L. M. et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol 77, 5721-5730 (2003).
19. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 31, 827-832, doi: 10.1038/nbt.2647 (2013).
20. Garcia, J. A. et al. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J 8, 765-778 (1989).
21. Dingwall, C. et al. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J 9, 4145-4153 (1990).
22. Roy, S., Parkin, N. T., Rosen, C., Itovitch, J. & Sonenberg, N. Structural requirements for trans activation of human immunodeficiency virus type 1 long terminal repeat-directed gene expression by tat: importance of base pairing, loop sequence, and bulges in the tatresponsive sequence. J Virol 64, 1402-1406 (1990).
23. Tiley, L. S., Malim, M. H., Tewary, H. K., Stockley, P. G. & Cullen, B. R. Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci USA 89, 758-762 (1992).
24. Mustafa, F. & Robinson, H. L. Context-dependent role of human immunodeficiency virus type 1 auxiliary genes in the establishment of chronic virus producers. J Virol 67, 6909-6915 (1993).
25. Chen, C. & Bundschuh, R. Systematic investigation of insertional and deletional RNA-DNA differences in the human transcriptome. BMC Genomics 13, 616 (2012).
26. Ronda, C. et al. Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnol Bioeng 111, 1604-1616 (2014).
27. Roy, S., Delling, U., Chen, C. H., Rosen, C. A. & Sonenberg, N. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev 4, 1365-1373 (1990).
28. Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H. & Jones, K. A. A novel CDK9-associated C-type cyclin interacts directly with HIV- 1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92, 451-462 (1998).
29. Wang, G., Zhao, N., Berkhout, B. & Das, A. T. CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Molecular therapy : the journal of the American Society of Gene Therapy 24, 522-526, doi: 10.1038/mt.2016.24 (2016).
30. Wang, Z. et al. CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell reports 15, 481-489, doi: 10.1016/j.celrep.2016.03.042 (2016).
31. Canver, M. C. et al. Characterization of genomic deletion efficiency mediated by clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem 289, 21312-21324, doi: 10.1074/jbc.M114.564625 (2014).
32. Lin, Y. et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res 42, 7473-7485 (2014).
33. Kearney, M. F. et al. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 10, e1004010 (2014).
34. Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nature methods 11, 783-784, doi: 10.1038/nmeth.3047 (2014).
35. Adachi, A. et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59, 284-291 (1986).
36. Page, K. A., Liegler, T. & Feinberg, M. B. Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 13, 1077-1081 (1997).